leisure time -WSS

leisure time

author：comprehensive 2025-09-28 02:31:47 - browse：65215

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： As AI in medicine takes off, can 'human in the loop' prevent harm?

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Ionis has late

How the Dana

Menendez indictment could see pharma lose a key ally

Ebola: Gilead Sciences antiviral shows promise as new treatment

focus

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: CAR

The cancer drug shortage isn’t new — and neither are the solutions

FDA seeks to regulate lab

The cancer drug shortage isn’t new — and neither are the solutions

Pushing for an NIH office for post

Anesthesiologist group: stop taking Ozempic before surgery

Biogen shutters digital health group, ends Apple study, in cost cutting move

Moonlake's readout produced a cash windfall. Risks remain

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

leisure time

RaDonda Vaught links Vanderbilt hospital issues to patient death

Listen: Who gets the credit for GLP

Did you have Obamacare on your GOP debate bingo card?

How many hemophilia patients actually want gene therapy?

FDA advisers back CAR

Sudafed saga points to U.S. issues with evaluating older drugs

knowledge

focus

leisure time

leisure time